Edwards Inspiris Resilia 生物瓣在肺动脉位置的早期令人担忧的结果
回顾性分析2019年8月至2021年10月单中心27例肺动脉位置植入Inspiris Resilia生物瓣的患者,中位随访16±8个月,13例(48%)出现新发瓣膜反流,其中6例(22%)进展为中度、3例(11%)为重度,3例(11%)再次行经导管瓣中瓣介入;无早期或晚期死亡。作者认为该瓣膜设计可能不适合低压循环或需改良植入技术。
要点
- 肺动脉位置植入Inspiris Resilia生物瓣后随访16±8个月,48%患者出现新发反流。
- 其中22%进展为中度反流、11%为重度反流,11%需再次经导管瓣中瓣介入。
- 无早期或晚期死亡,无晚期再次手术;标准手术技术植入者出现反流,管道植入者无反流。
核心结论
- 关于Inspiris Resilia生物瓣用于肺动脉位置的早期数据令人担忧。
- 该瓣膜设计可能不适合低压循环,或需要改良其植入技术。
研究设计与样本
- 回顾性分析2019年8月至2021年10月单中心肺动脉位置植入Inspiris Resilia生物瓣的27例患者(15例女性,56%;平均年龄22.26±14.99岁)。
主要发现
- 最常见原发病为法洛四联症(13例,48%),5例(18.5%)有既往经导管介入史,平均右室舒张末容积指数164.25±45.1 mL/m2。
- 胸骨切开或再次胸骨切开为最常见入路(21例,77.8%),22例(81.5%)采用标准肺动脉瓣置换技术,5例(18.5%)作为管道植入。
- 出院时6例(22.2%)存在微量至轻度人工瓣反流;随访期间13例(48%)出现新发人工瓣反流,均采用标准手术技术植入,管道植入病例无反流。
- 新发反流进展为中度6例(22%)、重度3例(11%),3例(11%)在手术肺动脉瓣置换后行经导管瓣中瓣介入。
- 无早期死亡,随访完整(平均16±8个月),无晚期死亡或晚期再次手术。
临床怎么用
- 作者认为Inspiris Resilia生物瓣用于肺动脉位置的早期结果令人担忧,该瓣膜设计可能不适合低压循环,或需改良植入技术。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Inspiris Resilia (Edwards Lifesciences LLC) bioprosthesis has gained widespread use in the aortic position; however no robust data are available about its use in the pulmonary position. METHODS: We reviewed our outcomes for the Inspiris Resilia in the pulmonary position between August 2019 and October 2021. RESULTS: Twenty-seven patients (15 female patients [56%]; mean age, 22.26 ± 14.99 years) were included. The most common original pathology was tetralogy of Fallot (13 patients, 48%). Five patients (18.5%) had prior transcatheter interventions. The mean right ventricular end-diastolic volume index was 164.25 ± 45.1 mL/m2. Sternotomy or repeat sternotomy was the most common approach (21 patients, 77.8%). The standard technique for pulmonary valve replacement was used in 22 patients (81.5%), whereas the prosthesis was implanted as a conduit in the remaining 5 (18.5%). Trivial to mild prosthetic regurgitation was present in 6 patients (22.2%) at the time of discharge. There was no early mortality. Follow-up was complete in all patients (mean, 16 ± 8 months), with no late mortality or late reoperations. New prosthetic regurgitation developed in 13 patients (48%), all of whom underwent replacement with the standard surgical technique. No regurgitation occurred in the conduit cases. This progressed to moderate regurgitation in 6 patients (22%) and severe in 3 (11%). Three patients (11%) underwent transcatheter valve-in-valve after their surgical pulmonary valve replacement. CONCLUSIONS: The early data regarding the Inspiris Resilia bioprosthesis use in the pulmonary position is concerning. The prosthesis design may not be suitable for low-pressure circulation, or modification of its implantation technique may be needed.
引用
- Said SM, Hiremath G, Aggarwal V, et al. Early Concerning Outcomes for the Edwards Inspiris Resilia Bioprosthesis in the Pulmonary Position. Ann Thorac Surg. 2022. PMID: 36174775. doi:10.1016/j.athoracsur.2022.09.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。